Skip to main content
Clinical Trials/NL-OMON23373
NL-OMON23373RecruitingNot Applicable

The effects of THIOpurine therapy on SEMEN quality in IBD patients: a prospective cohort study

TEVA Pharmaceuticals B.V.0 sites30 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
30

Study Overview

Brief Summary

The Association between Thiopurines and Male Fertility: a systematic review and meta-analysis

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • •All male Crohn’s disease or ulcerative colitis patients, aged between 18 and 50 years who will be treated with thiopurines, without prior exposure to thiopurines or possible spermatotoxic drugs

Exclusion Criteria

  • •Subject with prior treatment with thiopurines in three months before inclusion, prior treatment with possible spermatotoxic drugs (e.g. sulfasalazine, tacrolimus, busulfan, chlorambucil, cyclophosphamide, cyclosporine) or male patients with a known history of subfertility or infertility.

Investigators

Sponsor
TEVA Pharmaceuticals B.V.

Similar Trials

The effects of THIOpurine therapy on SEMEN... | Clinical Trial